Alopexx (ALPX) sets $10-$12 IPO range after dozens of amendments
As seen on the 24/7 Wall St. homepage on November 6, 2026.
Alopexx sets $10-$12 range for $33 million NYSE American IPO
Twenty-one amendments in, the anti-infective developer finally has terms worth pricing against: 3 million shares at $10 to $12, or roughly $33 million with ThinkEquity running the book. A deal this small on NYSE American leaves almost no float cushion once it trades.
Continue ReadingShow less
Alopexx, Inc. is an anti-infective drug developer whose long run of SEC amendments has finally produced pricing terms investors can evaluate: a proposed range of $10 to $12 per share, with ThinkEquity running the book.
At 3 million shares offered, this is a compact deal by any standard. That limited supply means the publicly traded float once the stock begins changing hands on NYSE American will carry almost no cushion, which tends to amplify price swings in either direction in the early sessions after listing.
Sponsored
The length of the amendment trail does not necessarily reflect on the underlying business, but it is context worth holding alongside the pricing terms as the deal moves toward a final number. Investors watching this IPO are waiting on the pricing decision that will confirm where within, above, or below the $10 to $12 range the shares actually come to market.
No final price has been set yet. That number, when it arrives, will set the opening tone for a stock where thin float leaves little room for a quiet debut.